

Editorial Disclosures for *Biological Psychiatry*

Biological Psychiatry recognizes the importance of considering potential editorial conflicts of interest when processing and evaluating manuscript submissions. We therefore provide this policy to the scientific community as a means of offering transparency to the editorial policies of the journal. Editors of *Biological Psychiatry* will provide public disclosures of their financial interests over the last two years, and will differentiate those relationships by yearly monetary values of less than or equal to \$10,000, and those greater than \$10,000. The single exception to the monetary designation is research study support in the form of drug *only* (no other financial or material support). When only the study drug is supplied for a project, this will be listed in the minor conflict category. Editors will recuse themselves from evaluating or handling a paper according to the following rules:

- 1) In the event of a major conflict of interest (greater than \$10,000), the editor having such conflict will not have any involvement in the editorial process, including but not limited to evaluating, reviewing, commenting on or otherwise participating in editorial decision-making, regarding any manuscript believed to be related to the source of the conflict in any way. By way of example, an editor will not involve him/herself with manuscripts where any of the authors are employed at the same institution as the editor, nor will an editor have any involvement in the editorial process regarding manuscripts investigating any drug manufactured by a company in which the editor has a major conflict (as listed and defined in this policy).
- 2) Also in relation to major conflicts (greater than \$10,000), in cases where an editor has consulted with a company on a particular drug, the editor will recuse him/herself from involvement in the editorial process with regard to the entire class of agents, regardless of the funding source of the manuscript.
- 3) For minor conflicts of interest (equal to or less than \$10,000) or those with drug support only, editors will recuse themselves from the editorial process in connection with manuscripts only in instances involving the specifics of their relationship (i.e., manuscripts that report on the specific drug with which the editor has a relationship).
- 4) Because not all potential conflicts of interest are financial in nature, editors shall recuse themselves from the editorial process regarding any manuscript in connection with which the editor believes he/she cannot provide an impartial, unbiased opinion. This includes, but is not necessarily limited to instances in which a personal relationship may exist, such as a mentorship or a scientific collaboration, or in cases where the scientific information may be in conflict with the editor's own scientific reporting/data. In considering whether a basis for recusal exists, an editor shall be guided by the need to avoid the appearance of conflict.
- 5) For submitted papers where an editor is a co-author, the manuscript will be handled by a member of the Society of Biological Psychiatry (SOBP) Editorial Committee who does not have a conflict of interest with respect to that editor/author or the other authors of the paper.

- 6) Interests or relationships belonging to an immediate family member of an editor constitute a major conflict of interest for said editor to the same extent that it would if such interest or relationship belonged to said editor directly. Any editor having such a family-related major conflict of interest shall recuse him/herself from the editorial process relating to all manuscripts where such conflict exists.
- 7) An editor shall not use any confidential information obtained from his/her editorial activities with *Biological Psychiatry* to further his/her own or others' financial interests or personal or professional gain.

Editor	Financial Relationships	
	Minor Conflicts or Less than or equal to \$10,000	Major Conflicts or Greater than \$10,000
Cameron S. Carter <i>Deputy Editor</i>	Eli Lilly and Co.: - <i>One time consultation</i> Hoffmann-La Roche Inc. (Roche): - <i>One time consultation</i> Merck: - <i>One time consultation</i> Pfizer Pharmaceuticals: - <i>One time consultation</i> Servier: - <i>One time consultation</i>	University of California, Davis: - <i>Employed</i>
Daniel Geschwind <i>Deputy Editor</i>	---	University of California, Los Angeles: - <i>Employed</i>
Paul J. Harrison <i>Deputy Editor</i>	Janssen: - <i>Chair, Scientific Meetings</i> - <i>Lecture Fees</i> Merck: - <i>Scientific Advisory Board</i> Organon: - <i>Lecture Fees</i> Schering Plough: - <i>Advisory Meeting</i> Wyeth: - <i>Scientific Advisory Board</i>	GlaxoSmithKline: - <i>Unrestricted Educational Grant</i> University of Oxford: - <i>Employed</i>
John H. Krystal <i>Editor</i>	Abbott Laboratories: - <i>Scientific Advisory Board member</i> Advantage Healthcare: - <i>Consultant</i> American College of Neuropsychopharmacology: - <i>Board of Directors</i> AstraZeneca Pharmaceuticals, LP: - <i>Consultant</i> Baker Botts, L.L.P.: - <i>Consultant</i> Bristol-Myers Squibb: - <i>Scientific Advisory Board member</i> Chesapeake Holding Company: - <i>Consultant</i>	Janssen Research Foundation: - <i>Research Support to Department of Veterans Affairs (supplied drug)</i> Pending Patents: - <i>Glutamate Agents in the Treatment of Mental Disorders</i> - <i>Intranasal Administration of Ketamine to Treat Depression</i> Pfizer Pharmaceuticals: - <i>Pfizer Neuroscience Therapeutic Area Scientific Advisory Panel (TASAP)</i> Takeda Industries: - <i>Scientific Advisory Board member</i> VA Connecticut Healthcare System: - <i>Employed</i>

	<p>Easton Associates, LLC: -Consultant</p> <p>Eli Lilly and Co.: -Scientific Advisory Board member -Provided access to data</p> <p>Forest Laboratories: -Scientific Advisory Board member</p> <p>Genactis: -Consultant</p> <p>GlaxoSmithKline: -Scientific Advisory Board member</p> <p>Leerink Swann: -Consultant</p> <p>Lhocla Research Corporation: -Scientific Advisory Board member</p> <p>Merz Pharmaceuticals: -Guest lecturer</p> <p>MK Medical Communications: -Consultant</p> <p>Neurogen Corporation: -Consultant</p> <p>Organon: -Scientific Advisory Board member</p> <p>Research Society on Alcoholism: -Board of Directors</p> <p>Roche Laboratories: -Consultant</p> <p>SK Holdings Co., Ltd.: -Consultant</p> <p>Tetragenex Pharmaceuticals: -Exercisable Warrant Options</p> <p>Transcept Pharmaceuticals, Inc.: -Scientific consultant</p>	<p>Yale University: -Employed</p>
<p>John S. March Deputy Editor</p>	<p>Eli Lilly and Co.: -Research Support (supplied drug) -Scientific Advisory Board member -Scientific consulting fees</p> <p>Guilford Press: -Royalties</p> <p>Johnson & Johnson: -DSMB member</p> <p>MedAvante: -Stocks (no current value)</p> <p>Oxford University Press: -Royalties</p> <p>Pfizer Pharmaceuticals: -Research Support (supplied drug) -Scientific Advisory Board member -Scientific consulting fees</p> <p>Wyeth: -Scientific consulting fees</p>	<p>Duke University: -Employed</p> <p>Multidimensional Anxiety Scale for Children (MultiHealth Systems): -Royalties</p>
<p>Eric J. Nestler Deputy Editor</p>	<p>EPIX Pharmaceuticals: -Scientific Advisory Board member</p> <p>Intra-Cellular Therapies, Inc.: -Scientific Advisory Board member</p> <p>NeuroMolecular Pharmaceuticals:</p>	<p>Merck Research Labs: -Scientific Advisory Board member</p> <p>Mount Sinai School of Medicine: -Employed</p> <p>Neurologix, Inc.:</p>

	<p><i>-Scientific Advisory Board member</i> Psylin Neurosciences: <i>-Scientific Advisory Board member</i> RxGen: <i>-Scientific Advisory Board member</i></p>	<p><i>-Scientific Advisory Board member</i> PsychoGenics: <i>-Founder and Chair</i> <i>-Scientific Advisory Board member</i> UT Southwestern Medical Center: <i>-Previously Employed (through July 08)</i></p>
<p>Jon-Kar Zubieta <i>Deputy Editor</i></p>	<p>---</p>	<p>Eli Lilly and Co.: <i>-Consultant</i> University of Michigan: <i>-Employed</i></p>